Free Republic

New clinical research shows that lamivudine, a reverse transcriptase inhibitor widely used in HIV therapy, stopped disease progression in 25% of patients with fourth-line metastatic colorectal cancer. Findings from the trial raise the possibility of an unexpected promising direction in cancer treatment, not just colorectal cancer. The trial included 32 patients with advanced metastatic colon cancer whose disease progressed despite four lines of previous cancer treatments. The first nine patients received the standard HIV-approved dose of lamivudine. "After giving them only this one drug—nothing else—we saw signs of disease stability," says co-senior author David T. Ting, MD, of the Mass...

US Ebola Death: Antivirals Submitted by admin on Wed, 10/08/2014 - 13:19 The first U.S. Ebola patient, Thomas Eric Duncan, has died despite being administered the experimental nucleoside-type antiviral pro-drug Brincidofovir.  How is this possible?  Well , the first problem is that Duncan was not treated until it was far too late for antiviral therapy to work.  Let's take this opportunity to look at some nucleoside antivirals, incuding the drug that was administered to Mr. Duncan in Dallas, TX (Brincidofovir).The first thing to know is remember Brincidofovir and Cidofovir were developed to work against dsDNA Viruses, though Ebola is a...

Dr. Gorbee Logan has given the drug, lamivudine, to 15 Ebola patients, and all but two survived. That's about a 13% mortality rate. Logan said he got the idea to try lamivudine when he read in scientific journals that HIV and Ebola replicate inside the body in much the same way. "Ebola is a brainchild of HIV," he said. "It's a destructive strain of HIV." At first he tried a drug called acyclovir, which is often given to HIV patients to treat infections that occur with their weakened immune systems. But it didn't seem to be effective. Then he tried...

Out of Control AIDS and the corruption of medical science Posted on Friday, April 7, 2006. Originally from Harper's Magazine, March 2006. By Celia Farber. Joyce Ann Hafford was a single mother living alone with her thirteen-year-old son, Jermal, in Memphis, Tennessee, when she learned that she was pregnant with her second child. She worked as a customer service representative at a company called CMC Call Center; her son was a top student, an athlete and musician. In April 2003, Hafford, four months pregnant, was urged by her obstetrician to take an HIV test. She agreed, even though she...

Chicago, Sept. 14, 2003 – A treatment regimen of Ziagen® (abacavir sulfate) (ABC), Epivir® (lamivudine) (3TC) and efavirenz (EFV) has been shown to be non-inferior to the often prescribed regimen of Retrovir® (zidovudine) (ZDV) and 3TC and EFV in a large Phase III clinical trial comparing virologic response in treatment-naïve HIV+ adults. The 48-week data from the trial (CNA30024) were reported here today at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Study CNA30024 enrolled therapy-naïve adults and randomized them to treatment with (1) ABC 300mg twice daily plus 3TC 150mg twice daily plus EFV 600mg once daily...